Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
Conditions: Fallopian Tube Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Recurrent Fallopian Tube Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Fallopian Tube Transitional Cell Carcinoma; Recurrent Fallopian Tube Undifferentiated Ca rcinoma; Recurrent High Grade Fallopian Tube Serous Adenocarcinoma; Recurrent High Grade Ovarian Serous Adenocarcinoma; Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma; Recurrent Low Grade Ovarian Serous Adenocarcinoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Ovarian Mucinous Adenocarcinoma; Recurrent Ovarian Transitional Cell Carcinoma; Recurrent Ovarian Undifferentiated Carcinoma; Recurrent Platinum-Resistant Fallopian Tube Carcinoma; Recurrent Platinum-Resistant Ov arian Carcinoma; Recurrent Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Primary Peritoneal Clear Cell Adenocarcinoma; Recurrent Primary Peritoneal Endometrioid Adenocarcinoma; Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma; Recurrent Primary Peritoneal Lo w Grade Serous Adenocarcinoma; Recurrent Primary Peritoneal Transitional Cell Carcinoma; Recurrent Primary Peritoneal Undifferentiated Carcinoma Interventions: Drug: Cediranib Maleate; Biological: Durvalumab; Drug: Olaparib; Drug: Paclitaxel; Drug: Pegylated L...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials